

# Differential Regulation of $\beta_1$ Integrins by Chemoattractants Regulates Neutrophil Migration through Fibrin

John D. Loike,\* Long Cao,\* Sadna Budhu,\* Eugene E. Marcantonio,† Joseph El Khoury,§ Stanley Hoffman,|| Ted A. Yednock,¶ and Samuel C. Silverstein\*

\*Department of Physiology and Cellular Biophysics and †Department of Pathology, Columbia University College of Physicians and Surgeons, New York 10032; ||Department of Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29425-2229; §Department of Medicine, Beth Israel Hospital, New York 10004; and ¶Athena Neurosciences, South San Francisco, California 94080

**Abstract.** Chemoattractants differ in their capacity to stimulate neutrophils to adhere to and to migrate through matrices containing fibrin. Formyl methionyl leucyl phenylalanine (fMLP) stimulates neutrophils to adhere closely to, but not to migrate into, fibrin gels. Leukotriene B4 (LTB4) stimulates neutrophils to adhere loosely to and to migrate through fibrin gels. We report that  $\alpha_5\beta_1$  integrins regulate the different migratory behaviors on fibrin gels of neutrophils in response to these chemoattractants. fMLP, but not LTB4, activated neutrophil  $\beta_1$  integrins, as measured by binding of mAb 15/7 to an activation epitope on the  $\beta_1$  integrins. Antibodies or peptides that block  $\alpha_5\beta_1$  integrins prevented fMLP-stimulated neutrophils from forming zones of close apposition on fibrin and reversed fMLP's

inhibitory effect on neutrophil chemotaxis through fibrin. In contrast, neither peptides nor antibodies that block  $\beta_1$  integrins affected the capacity of LTB4-stimulated neutrophils to form zones of loose apposition or to migrate through fibrin gels. These results suggest that chemoattractants generate at least two different messages that direct neutrophils, and perhaps other leukocytes, to accumulate at specific anatomic sites: a general message that induces neutrophils to crawl and a specific message that prepares neutrophils to stop when they contact appropriate matrix proteins for activated  $\beta_1$  integrins.

**Key words:** chemotaxis • neutrophils • integrins • fibrin • chemoattractants

LEUKOCYTE chemotaxis is regulated by the interactions of soluble or surface-bound chemoattractants/chemokines with cognate receptors on the leukocytes. These interactions generate intracellular signals that activate one or more of the leukocyte's adhesion-promoting receptors, thereby enabling these cells to adhere to or migrate through endothelia, epithelia, and extracellular matrices.

Neutrophils (polymorphonuclear leukocytes, PMN)<sup>1</sup> express a number of different adhesion-promoting surface receptors, including  $\beta_1$  and  $\beta_2$  integrins.  $\beta_2$  integrins assume an "activated" conformation when chemoattractants,

chemokines, cytokines, or growth factors bind to specific receptors for these substances on PMN (Diamond and Springer, 1994; Premack and Schall, 1996). Activation increases the capacity of  $\beta_2$  integrins to bind cognate ligands on cells or matrix proteins, thereby regulating PMN adhesion to and migration through endothelia (Smith, 1993; Springer, 1995), epithelia (McCormick et al., 1995), layers of synovial fibroblasts (Gao et al., 1995; Gao and Issekutz, 1996), and extracellular matrices (Wright et al., 1988; Loike et al., 1991, 1992, 1995). The central roles played by  $\beta_2$  integrins in PMN adhesion and chemotaxis in vivo are illustrated by the multiple derangements of PMN function in humans with the inherited disorder leukocyte adhesion deficiency type 1, in which there is partial to complete absence of  $\beta_2$  chains (Anderson and Springer, 1987), and in mice rendered functionally or genetically deficient in  $\alpha_M\beta_2$  (CD11b/CD18) integrin (Tang et al., 1997).

PMN also express  $\beta_1$  integrins, primarily  $\alpha_3\beta_1$ ,  $\alpha_5\beta_1$ , and  $\alpha_6\beta_1$ , but also very low levels of  $\alpha_4\beta_1$  (Gao et al., 1995; Gresham et al., 1996) that participate in PMN adhesion, migration, and phagocytosis. For example, C5a, a cleavage product of the fifth component of complement, and PMA stimulate  $\alpha_5\beta_1$ -dependent PMN adherence to fibronectin

Address correspondence to Dr. John D. Loike, Department of Physiology and Cellular Biophysics, Columbia University College of Physicians and Surgeons, 630 W. 168th St., Mail hub #22, New York, NY 10032. Tel.: (212) 305-1510. Fax: (212) 305-5775. E-mail: jdl5@columbia.edu

1. *Abbreviations used in this paper:* C3bi, cleaved b fragment of the 3rd complement component; C5a, a fragment of the cleaved 5th complement component; fMLP, formyl methionyl leucyl phenylalanine; HSA, human serum albumin; IL-8, interleukin 8; LTB4, leukotriene B4; PMN, polymorphonuclear leukocytes; Rh-PEG, rhodamine-conjugated polyethylene glycol.

(Bohnsack et al., 1995). Chemoattractant-activated  $\beta_1$  integrins work in concert with  $\alpha_M\beta_2$  (CD11b/CD18) integrins to mediate phagocytosis of particles coated with C3bi by PMN (Pommier et al., 1983; Wright et al., 1984; Brown, 1992).  $\beta_1$  integrins also mediate chemotaxis of platelet activating factor-stimulated rat PMN (Werr et al., 1998).

We reported previously (Loike et al., 1995) that different chemoattractants specify qualitatively distinct PMN responses when PMN contact specific matrix proteins. For example, PMN stimulated with formyl methionyl leucyl phenylalanine (fMLP) or tumor necrosis factor- $\alpha$  form zones of close apposition on fibrin and do not migrate through fibrin gels, whereas PMN stimulated with leukotriene B4 (LTB4) or interleukin 8 (IL-8) form zones of loose apposition on fibrin and migrate efficiently into and through fibrin gels (Loike et al., 1995). All of these chemoattractants activate PMN  $\beta_2$  integrins (Diamond and Springer, 1994; Premack and Schall, 1996) and induce PMN to migrate efficiently through three-dimensional matrices composed of Matrigel or collagen I (Loike et al., 1995). Antibodies that block the ligand-binding domains of  $\beta_2$  integrins inhibit PMN migration through all matrices tested (i.e., collagen I, Matrigel, and fibrin), in response to chemoattractants. Therefore, it seemed unlikely that the different effects of fMLP and LTB4 on PMN chemotaxis through fibrin gels could result from small differences in the effects of these chemoattractants on  $\beta_2$  integrins.

$\beta_1$  integrins regulate the activity of  $\alpha_M\beta_2$  integrins on PMN (Brown, 1992) and monocytes (Pommier et al., 1983; Wright et al., 1984), and of  $\alpha_{III}\beta_3$  integrins on platelets (Loike et al., 1993). We reasoned that fMLP, but not LTB4, might activate one or more PMN  $\beta_1$  integrins and that signals generated by the interaction of activated  $\beta_1$  integrins with ligands on fibrin might affect PMN chemotaxis. To test this hypothesis we examined the effects of fMLP and LTB4 on activation of PMN  $\beta_1$  integrins, and of antibodies and peptides that block  $\beta_1$  integrins on fMLP- and LTB4-stimulated PMN adhesion to and migration through fibrin gels. We report here that fMLP, but not LTB4, activates  $\beta_1$  integrins on PMN, and that the interaction of activated  $\beta_1$  integrins with fibrin alters the quality of  $\beta_2$  integrin-dependent adhesion to, and migration through, fibrin gels.

## Materials and Methods

### Reagents

Rhodamine-conjugated polyethylene glycols of 3.5 kD (Rh-PEG 3.5 kD) and 10 kD (Rh-PEG 10 kD) were prepared as described (Loike et al., 1993, 1995). Sources of antibodies and peptides were as follows: mouse anti- $\beta_1$  (P4C10) and the peptides GRGDSP and GRGESP were from GIBCO BRL. Mouse anti-human  $\alpha_x$  (LeuM5) was from Organon-Teknika Inc. Mouse anti-human  $\alpha_M\beta_2$  (MAC-1) was from Upstate Biotechnology Co. Mouse anti-human  $\alpha_5$  (SAM1), rat anti-human  $\alpha_6$  (GoH3), mouse anti-human  $\alpha_4$  (HP2/1), and mouse anti-human  $\beta_3$  integrin (SZ21) were from Immunotech. Phycoerythrin-conjugated F(ab)<sub>2</sub> anti-mouse IgG was from Jackson ImmunoResearch. Mouse anti- $\beta_3$  (PPM6/13) was from Biosource International. Mouse anti- $\beta_3$  (MAB1957z) was from Chemicon International. Alexa 488-conjugated F(ab)<sub>2</sub> anti-mouse IgG was from Molecular Probes. LTB4, fMLP, PMA, thrombin, and Ficoll-Hypaque were from Sigma Chemical Co. Mouse anti-chicken  $\beta_1$  integrin (CSAT) and mouse monoclonal anti-human  $\beta_1$  integrin (AiiB2) were generous gifts from Dr. Clayton Buck (University of California, San Francisco, CA). Mouse mAb 15/7, which recognizes an activa-

tion epitope on human  $\beta_1$  integrins (Bohnsack et al., 1995), was from Athena Neurosciences. Mouse mAb IB4, which blocks the ligand-binding domains of human  $\beta_2$  integrins (Wright et al., 1983), was a generous gift from Dr. Samuel D. Wright (Merck, Rahway, NJ). PPACK was from Calbiochem-Novabiochem, Matrigel from Becton Dickinson, and collagen I from GIBCO BRL. Purified fibronectin was from Vitex International. Fibrinogen was from American Diagnostica Inc. Fibrinogen uncontaminated by Factor XIII, fibronectin, and vitronectin, a generous gift of Dr. Jeffrey Weitz (MacMaster University, Hamilton, Ontario, Canada), was prepared from fibrinogen obtained from Enzyme Research Labs FIBI. It was first adsorbed with gelatin-agarose to remove fibronectin and then passed over an affinity column to remove Factor XIII. The fibrinogen was precipitated with 25% ammonium sulfate, dialyzed against 150 mM NaCl, 20 mM Tris (pH 7.4), adsorbed with an antibody to human vitronectin linked to Affi-gel, and dialyzed. PAGE analysis showed the resulting fibrinogen to be free of fibronectin or Factor XIII. Western blot analysis revealed no vitronectin (data not shown).

### Preparation of Boyden-type Chemotaxis Chambers

Gels, ~1 mm thick, composed of fibrin, Matrigel, or collagen type IV, were formed in cell culture inserts (pore sizes 3 or 8  $\mu$ m) from Becton Dickinson as described (Loike et al., 1995). Fibrin gels were gently washed with PBS to remove any residual PPACK.

### PMN Adhesion and Closeness of Apposition to Fibrin-coated Surfaces

Fibrin/fibrinogen-coated surfaces were prepared as described (Wright et al., 1988; Loike et al., 1992, 1993, 1995) and PMN adhesion was measured by phase-contrast microscopy. Close apposition of PMN to fibrin/fibrinogen-coated surfaces was defined as exclusion of Rh-PEG 10 kD from zones of contact between PMN and fibrin/fibrinogen measured by fluorescence microscopy as described (Loike et al., 1993).

### PMN Migration

PMN were prepared as described (Wright et al., 1988) from fresh heparinized blood from healthy adult donors after informed consent. PMN used in these experiments were >95% pure as determined by Wright-Giemsa staining (Wright et al., 1988).  $10^6$  PMN in 100  $\mu$ l of PBS supplemented with 5.5 mM glucose and 0.1% human serum albumin (PBSG-HSA) were placed in the upper compartment of each insert and incubated for 0–6 h at 37°C in a humidified atmosphere containing 95% air/5% CO<sub>2</sub>. At the times and concentrations specified, chemoattractants, antibodies, and/or peptides were added to the top and/or bottom compartments in 500  $\mu$ l of PBSG-HSA. At the end of incubations, chambers were shaken to dislodge PMN from the lower surface of the inserts. The medium in each lower compartment was collected and its content of PMN was determined using a Coulter counter (Loike et al., 1995). Unless otherwise indicated, all values reported are the average of six different samples from at least three independent experiments.

### Flow Cytometric Analysis

PMN ( $10^5$  cells/200  $\mu$ l of PBSG-HSA) were incubated in suspension at 37°C for 30 min in the presence or absence of fMLP ( $10^{-7}$  M) or LTB4 ( $10^{-7}$  M), transferred to 96-well polystyrene tissue culture microtiter plates (Corning), incubated for 30 min at 4°C in 200  $\mu$ l PBSG-HSA containing the indicated primary antibody (2  $\mu$ g/ml), washed three times with PBSG-HSA at 4°C, further incubated for 30 min at 4°C with either Alexa 488-conjugated or phycoerythrin-conjugated rabbit anti-mouse F(ab')<sub>2</sub> in 200  $\mu$ l of PBSG-HSA, washed three times again with PBSG-HSA at 4°C, and resuspended at 4°C in 300  $\mu$ l PBS containing 2% BSA and 0.3 mg/ml propidium iodide to determine cell viability. The contribution of dead cells (usually <2%) was removed from the final data analysis. The mean fluorescence intensity of  $3\text{--}5 \times 10^3$  cells was determined using a Becton Dickinson FACSCalibur®.


## Results

### PMN Chemotaxis through Matrigel and Fibrin Gels


PMN chemotax through three-dimensional gels composed

of reconstituted basement membrane proteins containing collagen IV, laminin, and fibronectin (Matrigel; Fig. 1), or collagen I (Loike et al., 1995) in response to a gradient of fMLP or LTB<sub>4</sub>. In contrast, PMN chemotaxis through fibrin gels or plasma clots is dependent upon the specific chemoattractant used. fMLP-stimulated PMN do not migrate through fibrin gels or plasma clots, whereas LTB<sub>4</sub>-stimulated PMN do (Fig. 2 A; Loike et al., 1995). Checkerboard analyses confirmed that PMN migrate through these gels in response to a chemoattractant gradient (Loike et al., 1995). Placement of equimolar concentrations of both fMLP and LTB<sub>4</sub> into the bottom chambers inhibited PMN from migrating through fibrin gels (Fig. 2 A; Loike et al., 1995), confirming that fMLP's effect is dominant over LTB<sub>4</sub>'s effect.

Commercial fibrinogen contains small amounts of fibronectin and vitronectin. To test whether matrix components other than fibrin are responsible for inhibiting migration of fMLP-stimulated PMN through fibrin gels and plasma clots, we performed additional experiments using fibrin gels formed from purified fibrinogen that contained no detectable fibronectin, plasminogen, Factor XIII, or vitronectin. PMN stimulated with LTB<sub>4</sub>, but not with fMLP, migrated through gels formed from purified fibrinogen (Fig. 2 B). Moreover, collagen I gels (60 μg/insert) each containing 10 μg of purified fibronectin did not affect the migration of either fMLP- or LTB<sub>4</sub>-stimulated PMN, whereas the addition of fibrinogen to such gels blocked migration of fMLP-stimulated PMN (data not



**Figure 1.** Effects of mAbs against β<sub>1</sub> and β<sub>2</sub> integrins on PMN chemotaxis through inserts precoated with Matrigel. 0.1 ml PBS containing 22 μg of Matrigel was placed into each culture insert (pore size = 8 μm) and allowed to gel at room temperature for 24 h. 10<sup>6</sup> PMN in 250 μl PBSG-HSA were placed in the upper compartment of each insert. 10<sup>-7</sup> M LTB<sub>4</sub> or 10<sup>-7</sup> M fMLP in 250 μl of PBSG-HSA was added to the bottom compartment. Where indicated, PMN were preincubated at 4°C for 30 min in PBSG-HSA containing 2 μg/ml of either anti-β<sub>1</sub> or anti-β<sub>2</sub> antibodies before adding the cells to the upper compartment of the inserts. Inserts were incubated for 6 h at 37°C, at which time the medium in each lower compartment was collected and its PMN content was determined using a Coulter counter. Reported are the average number ± SEM of PMN that migrated into the lower compartment from at least two samples in each of three independent experiments.




**Figure 2.** LTB<sub>4</sub> but not fMLP promotes PMN migration through fibrin gels. Fibrin gels were prepared from commercial fibrinogen (A) or from purified fibrinogen (B) and formed on top of filters (8-μm pores) in tissue culture inserts as described in Materials and Methods. 10<sup>6</sup> PMN were added to the upper chamber and 5 × 10<sup>-8</sup> M fMLP or 10<sup>-7</sup> M LTB<sub>4</sub> was added to either the lower or upper chamber as indicated. Where indicated, PMN were preincubated with antibodies against β<sub>1</sub> (AiiB<sub>2</sub>) or against α<sub>5</sub>β<sub>1</sub> (SAM<sub>1</sub>) integrins at 2 μg/ml for 30 min at 4°C and the mixture was added to the upper chamber. Inserts were incubated at 37°C for 6 h, at which time the number of cells in the lower chamber was determined using a Coulter counter.

shown). These results are consistent with reports (Asakura et al., 1997; Farrell and al-Mondhiry, 1997; Suehiro et al., 1997; Miettinen et al., 1998) that fibrin(ogen) contains sequences that are ligands for β<sub>1</sub> integrins, and confirm that fibrin is the matrix component that inhibits migration of fMLP-stimulated PMN.

#### Effects of Antibodies against β<sub>1</sub> and β<sub>2</sub> Integrins on PMN Chemotaxis through Fibrin Gels and Matrigel

To examine the roles of β<sub>1</sub> and β<sub>2</sub> integrins in PMN migration through Matrigel (Fig. 1), or fibrin (Figs. 2 A and 3), we added antibodies that block β<sub>1</sub> or β<sub>2</sub> integrins to the upper compartment of Matrigel or fibrin-coated inserts together with PMN and measured the number of PMN that migrated into the lower compartment in response to fMLP or LTB<sub>4</sub>. As expected, mAb IB<sub>4</sub>, directed against β<sub>2</sub> integrins (Wright et al., 1983), blocked PMN migration through Matrigel (Fig. 1) or fibrin gels (Fig. 2 A) in response to LTB<sub>4</sub>. Antibody IB<sub>4</sub> also blocked fMLP-stimulated PMN migration through Matrigel (Fig. 1), and did not alter fMLP's inhibitory effect on PMN chemotaxis through fibrin gels (data not shown). These results are consistent with previous reports (Diamond and Springer, 1994; Springer, 1995; Premack and Schall, 1996) that anti-β<sub>2</sub> integrin antibodies block PMN migration through endothelia and through gels formed by a variety of extracellular matrix proteins.

In contrast, mAbs AiiB<sub>2</sub> (Bohnsack et al., 1990) and P4C10 (Carter et al., 1990), which block the common β chain of β<sub>1</sub> integrins (CD29), had no effect on fMLP- or LTB<sub>4</sub>-stimulated chemotaxis through Matrigel (Fig. 1), or on LTB<sub>4</sub>-stimulated PMN migration through fibrin gels



**Figure 3.** Effects of anti-β<sub>1</sub> and anti-β<sub>2</sub> integrins on PMN chemotaxis through fibrin-coated inserts or Matrigel-coated inserts. Inserts were prepared as described in Fig. 1. Where indicated, PMN were preincubated for 30 min at 4°C with 2 μg/ml of one of the following mAbs: mouse anti-β<sub>1</sub> (P4C10), mouse anti-human α<sub>4</sub> (HP2/1), mouse anti-human α<sub>5</sub> (SAM1), or rat anti-human α<sub>6</sub> (GoH3), or with 1 mg/ml of GRGDSP peptide. The mixture was then added to the upper compartment of fibrin-coated inserts. 10<sup>-7</sup> M LTB4 or 5 × 10<sup>-8</sup> M fMLP was placed in the lower compartment, and the inserts were incubated at 37°C for 6 h. The number of PMN in the lower compartment was assayed as described in Fig. 1.

(Fig. 2 A). However, these same anti-β<sub>1</sub> chain antibodies reversed fMLP's inhibitory effect on PMN chemotaxis through fibrin (Fig. 3 A).

Control experiments showed that CSAT (Lallier and Bronner-Fraser, 1991), a mAb that binds to chicken but not human β<sub>1</sub> integrins, SZ21, an antibody against β<sub>3</sub> integrins (Lawson and Maxfield, 1995), and PM6/13, another antibody against β<sub>3</sub> integrins (Patel et al., 1998), did not alter the inhibitory effect of fMLP on PMN migration through fibrin gels (Fig. 3 A and data not shown). These antibodies also did not affect migration of LTB4-stimulated PMN through fibrin gels (data not shown).

Among the antibodies directed against the α chains of β<sub>1</sub> integrins, only those directed against α<sub>5</sub> chains were effective in reversing fMLP's inhibitory effect on PMN migration through fibrin gels (Figs. 2 B and 3 A). Neither antibodies against α<sub>4</sub> chains nor antibodies against α<sub>6</sub> chains of β<sub>1</sub> integrins affected migration of fMLP- or LTB4-stimulated PMN through fibrin gels (Fig. 3 A) or Matrigel (Fig. 3 B and data not shown).

To confirm that β<sub>1</sub> integrins directly interact with fibrin(ogen), we examined the effects of anti-β<sub>1</sub> integrins on the migration of fMLP-stimulated PMN through gels formed of purified fibrinogen, lacking detectable levels of fibronectin, vitronectin, plasminogen, or Factor XIII. Both antibodies directed against β<sub>1</sub> and α<sub>5</sub> chains of β<sub>1</sub> integrins (Fig. 2 B) reversed fMLP's inhibitory effect on chemotaxis through these gels. These results are consistent with reports (Asakura et al., 1997; Farrell and al-Mondhiry, 1997; Suehiro et al., 1997; Miettinen et al., 1998) that fibrin(ogen) contains sequences that are ligands for β<sub>1</sub> integrins.

**Table I.** Effect of RGD-containing Peptides on fMLP- and LTB4-stimulated PMN Chemotaxis through Fibrin Gels

| Additions | Chemoattractant | PMN in lower compartment (× 10 <sup>-3</sup> ) |
|-----------|-----------------|--|
| None      | fMLP            | 3 ± 1  |
| GRGDSP    | fMLP            | 50 ± 5   |
| GRGESp    | fMLP            | 2 ± 1  |
| None      | LTB4            | 135 ± 30                                       |
| GRGDSP    | LTB4            | 170 ± 50                                       |
| GRGESp    | LTB4            | 110 ± 40                                       |

10<sup>6</sup> PMN were preincubated for 30 min at 4°C with PBSG-HSA alone or containing 1 mg/ml GRGDSP or GRGESp before adding the mixture to the upper compartment of chemotaxis chambers. LTB4 (10<sup>-7</sup> M) or fMLP (10<sup>-7</sup> M) was added to the lower compartment, the chambers were incubated at 37°C for 6 h, and the number of PMN that migrated into the lower compartment was determined, all as described in Fig. 1. Values represent the average ± SEM of triplicate samples from three experiments.


The peptide GRGDSP blocks the interaction of β<sub>1</sub> integrins with RGD ligands on matrix proteins (Pierschbacher and Ruoslahti, 1987). Like antibodies against β<sub>1</sub> integrins, addition of GRGDSP peptide to the medium allowed fMLP-stimulated PMN to migrate through fibrin gels (Table I). Control experiments showed that GRGESp peptide, which does not block binding of β<sub>1</sub> integrins to fibronectin or other RGD-containing matrix proteins (Pierschbacher and Ruoslahti, 1987), did not reverse the inhibitory effect of fMLP on PMN migration through fibrin gels (Table I). Neither peptide affected the number of PMN that migrated through fibrin in response to LTB4 (Table I) or through Matrigel in response to fMLP (Fig. 3 B).

#### Effects of Antibodies against β<sub>1</sub> and β<sub>2</sub> Integrins on Adhesion of Chemoattractant-stimulated PMN to Fibrin

PMN were incubated in control medium or in medium containing fMLP or LTB4 and allowed to adhere to fibrin-coated 96-well plates. In the absence of chemoattractant <1% PMN adhered to fibrin (data not shown). Over 40% of fMLP-stimulated PMN and ~50% of LTB4-stimulated PMN adhered to fibrin. mAb IB4, which blocks the ligand-binding sites of three different β<sub>2</sub> integrins (α<sub>L</sub>β<sub>2</sub>, α<sub>M</sub>β<sub>2</sub>, and α<sub>X</sub>β<sub>2</sub>; Wright et al., 1983; Loike et al., 1991), inhibited adhesion of fMLP- or LTB4-stimulated PMN to fibrin by 75–80% (Fig. 4). In contrast, mAb AiiB2, which blocks the ligand-binding sites of β<sub>1</sub> integrins (Bohnsack et al., 1990), had no significant effect on the number of fMLP-stimulated PMN that adhered to fibrin, and enhanced by ~25% adhesion of LTB4-stimulated PMN to fibrin (Fig. 4). These experiments show that β<sub>2</sub> integrins are the primary PMN surface receptors that mediate adhesion of chemoattractant-stimulated PMN to fibrin.

#### fMLP, but Not LTB4, Activates PMN α<sub>5</sub>β<sub>1</sub> Integrins

The findings presented above indicate that β<sub>1</sub> integrins, and specifically α<sub>5</sub>β<sub>1</sub> integrins, mediate the qualitatively distinct effects of fMLP and LTB4 on PMN adhesion to, and migration through, fibrin gels. To determine whether fMLP and LTB4 differentially affect the activation of β<sub>1</sub> integrins we used mAb 15/7, which recognizes a confor-




**Figure 4.** Effect of anti-β<sub>1</sub> and anti-β<sub>2</sub> antibodies on adhesion of fMLP- or LTB<sub>4</sub>-stimulated PMN to fibrin-coated surfaces.  $5 \times 10^3$  PMN in  $5 \mu\text{l}$  PBSG-HSA containing  $10^{-7}$  M fMLP or  $10^{-7}$  M LTB<sub>4</sub> were allowed to settle for 30 min at 4°C in the presence or absence of the indicated antibody (10 μg/ml) onto each well of a 96-well plate that had been precoated with fibrin. Then, cells were warmed to 37°C for 15 min. The plates were washed, fixed, and counted as described (Wright et al., 1988).

mationally determined epitope on activated β<sub>1</sub> integrins (Bohnsack et al., 1995). PMN incubated for 30 min with fMLP exhibited a 10–22-fold increase in binding of mAb 15/7 (Fig. 5 J), compared with unstimulated PMN (Fig. 5 B), whereas PMN incubated for the same length of time with LTB<sub>4</sub> (Fig. 5 F) showed little change over unstimulated PMN (Fig. 5 B) with respect to binding of mAb 15/7. Control experiments showed that surface expression of β<sub>1</sub> integrins was stimulated approximately twofold by LTB<sub>4</sub> (Fig. 5 G), and approximately threefold by fMLP (Fig. 5

K), whereas β<sub>2</sub> integrin surface expression was stimulated approximately fivefold by LTB<sub>4</sub> (Fig. 5 H) and approximately ninefold by fMLP (Fig. 5 L). Other studies showed that the extent of expression of the epitope for antibody 15/7 on β<sub>1</sub> integrins was dependent upon the dose of fMLP used to stimulate the PMN, and that  $5 \times 10^{-6}$  M fMLP induced maximal expression of this epitope (not shown). In contrast, LTB<sub>4</sub> concentrations 10–50-fold higher (i.e.,  $10^{-6}$  to  $5 \times 10^{-6}$  M) than those used in the experiments described in Fig. 5 did not increase expression of the 15/7 epitope on β<sub>1</sub> integrins (data not shown).


### Effects of Antibodies against β<sub>1</sub> Integrins on Closeness of Apposition of fMLP- and LTB<sub>4</sub>-stimulated PMN to Fibrin

We have used exclusion of Rh-PEG 10 kD from zones of contact between chemoattractant-stimulated PMN and fibrin-coated surfaces as a measure of the closeness of apposition of PMN to the underlying substrate (Loike et al., 1995). Previously, we reported an inverse correlation between the formation of zones of close apposition between chemoattractant-stimulated PMN and fibrin gels and the capacity of PMN to migrate through these gels (see Fig. 7 in Loike et al., 1995). In the present experiments we used exclusion of Rh-PEG 10 kD to test whether antibodies and peptides that block β<sub>1</sub> integrins, and that facilitate migration of fMLP-stimulated PMN through fibrin gels (Figs. 2 and 3 A and Table I), affect the closeness of apposition of these cells to fibrin. Antibodies against the β chain of β<sub>1</sub> integrins, or against the α<sub>5</sub> chain of α<sub>5</sub>β<sub>1</sub> integrins (not shown), reduced the percentage of fMLP-stimulated PMN that excluded Rh-PEG 10 kD from zones of contact with fibrin from 80% to 20–30% (Fig. 6), and reduced the percentage of LTB<sub>4</sub>-stimulated PMN that excluded Rh-PEG 10 kD from these contact zones from 20% to <2% (Fig.



**Figure 5.** Effect of fMLP and LTB<sub>4</sub> on activation of PMN β<sub>1</sub> integrins. Fluorescence intensity of PMN incubated as described in Materials and Methods with Alexa 488-conjugated rabbit F(ab')<sub>2</sub> anti-mouse IgG alone (A, E, and I), with mAb 15/7 that recognizes an activation epitope on β<sub>1</sub> integrins followed by Alexa 488-conjugated F(ab')<sub>2</sub> anti-mouse IgG (B, F, and J), with mAb CD29 that recognizes the β chain of human β<sub>1</sub> integrins followed by Alexa 488-conjugated F(ab')<sub>2</sub> anti-mouse IgG (C, G, and K), or with a mAb that recognizes α<sub>M</sub>β<sub>2</sub> (CD11b/CD18) followed by Alexa 488-conjugated rabbit F(ab')<sub>2</sub> anti-mouse IgG (D, H, and L). Unstimulated PMN (A–D), LTB<sub>4</sub>-stimulated PMN (E–H), fMLP-stimulated PMN (I–L). fMLP and LTB<sub>4</sub> were each used at  $10^{-7}$  M.





**Figure 6.** Effect of anti- $\beta_1$  integrin antibodies on formation of zones of close apposition between PMN and fibrin-coated surfaces.  $5 \times 10^3$  PMN in  $30 \mu\text{l}$  PBSG-HSA containing  $10^{-7}$  M fMLP, or  $10^{-7}$  M LTB4, were allowed to adhere to each fibrin-coated spot of multispot slides in the presence or absence of P4C10 anti- $\beta_1$  integrin antibody ( $2 \mu\text{g/ml}$ ) for 30 min at  $37^\circ\text{C}$ . The preparations were further incubated at room temperature for 30 min with either fluorescein-conjugated antifibrinogen IgG (Loike et al., 1995), Rh-PEG 10 kD, or Rh-PEG 3.5 kD (Loike et al., 1992, 1993, 1995) and examined by epifluorescence microscopy. A zone of close apposition is defined as a region between adherent PMN and the underlying matrix from which fluorophore-conjugated probe is excluded. Values are expressed as the percentage of adherent PMN that forms such zones. Note that Rh-PEG 3.5 kD stained the surfaces uniformly, confirming the presence of fibrin underneath all adherent PMN and showing that molecules of 3.5 kD penetrate zones of close apposition.

6). These experiments together with those shown in Fig. 5 show there is a direct correlation between the capacity of fMLP or LTB4 to activate PMN  $\beta_1$  integrins and the capacity of these chemoattractants to promote close apposition between PMN and fibrin (as measured by exclusion of Rh-PEG 10 kD), and to inhibit PMN migration through fibrin gels (Fig. 3 A).

### Effects of Phorbol Esters on PMN Adhesion and Migration

Tumor-promoting phorbol esters, like ligands that bind to PMN and macrophage fibronectin receptors, activate  $\alpha_M\beta_2$  (CD11b/CD18) for phagocytosis of C3bi-coated particles (Wright and Silverstein, 1982), and promote formation of zones of close apposition between phorbol ester-stimulated PMN and fibrinogen-coated surfaces (Table II). However, phorbol ester-stimulated PMN do not migrate into fibrin gels, even when treated with antibodies against  $\alpha_5\beta_1$  integrins (data not shown). These findings suggested that phorbol esters activate  $\alpha_M\beta_2$  integrins for close apposition to fibrin independently of  $\beta_1$  integrins. To test this prediction, PMN were incubated with or without antibodies against  $\beta_1$  integrins, allowed to adhere to fibrin- or fibrinogen-coated surfaces in medium containing PMA, and then were incubated with Rh-PEG 10 kD. 77% of PMA-treated PMN formed zones of close apposition on fibrin even when they had been treated with antibodies against

**Table II.** Effect of Antibodies against  $\beta_1$  or  $\beta_2$  Integrins on Formation of Zones of Close Apposition to Fibrin by PMA-stimulated PMN

| Additions       | Percent of PMN forming zones of close apposition |                            |
|-----------------|--|----------------------------|
|                 | Fibrin-coated surfaces                           | Fibrinogen-coated surfaces |
| None            | $78 \pm 6$                                       | $94 \pm 2$                 |
| Anti- $\beta_1$ | $77 \pm 3$                                       | $95 \pm 1$                 |
| Anti- $\beta_2$ | $12 \pm 4$                                       | $14 \pm 5$                 |

$5 \times 10^3$  PMN stimulated with PMA ( $300 \text{ ng/ml}$ ) in  $30 \mu\text{l}$  PBSG-HSA were allowed to adhere to each fibrin- or fibrinogen-coated spot of multispot slides in the presence or absence of P4C10 anti- $\beta_1$  integrin antibody ( $2 \mu\text{g/ml}$ ) for 30 min at  $37^\circ\text{C}$ . The preparations were further incubated at room temperature for 30 min with Rh-PEG 10 kD, and examined by epifluorescence microscopy. A zone of close apposition is defined as described in Fig. 6. Values represent the average  $\pm$  SEM of triplicate samples from three experiments.

$\beta_1$  integrins. In contrast,  $<15\%$  of the PMA-stimulated PMN that adhered to these surfaces formed zones of close apposition when treated with antibodies against  $\beta_2$  integrins (Table II). This experiment shows that when suitably activated,  $\beta_2$  integrins are capable of mediating close apposition between PMN and fibrin-coated surfaces in the absence of  $\beta_1$  integrin ligation.

### Discussion

The different effects of fMLP and LTB4 on PMN adhesion to and chemotaxis through fibrin gels appear to be a consequence of qualitative differences in the effects of these chemoattractants on the activity of  $\beta_1$  integrins. That is, fMLP activates  $\beta_1$  integrins (Fig. 5 and Table III), stimulates PMN to adhere closely to fibrin(ogen) (Fig. 6 and Table III; Loike et al., 1995), and inhibits PMN chemotaxis through fibrin gels (Fig. 2 and Table III; Loike et al., 1995). In contrast, LTB4 neither activates  $\beta_1$  integrins (Fig. 5 and Table III) nor induces PMN to adhere closely to fibrin(ogen) (Fig. 6 and Table III; Loike et al., 1995), and stimulates PMN to migrate through fibrin gels (Fig. 2 and Table III; Loike et al., 1995). To our knowledge, this is the first demonstration that signals initiated by two chemically distinct chemoattractants with their respective seven membrane spanning/heterotrimeric G protein-coupled receptors exert different effects on the activation state of a specific  $\beta_1$  integrin, and regulate PMN migration.

### Fibrin(ogen)-containing Matrices Exert a Specific Effect

As shown in Fig. 2, fibrin(ogen) is unique among the matrix and plasma proteins tested in arresting the migration of fMLP-stimulated PMN. This is particularly notable in the case of fibronectin, a well-recognized ligand for  $\alpha_5\beta_1$  integrins. The failure of fibronectin to induce migration arrest suggests that fibrin(ogen) has heretofore unrecognized properties, independent of its ability to bind  $\alpha_5\beta_1$  integrins, that are important in its ability to cause migration arrest.

### Relationship between Closeness of Apposition, Tightness of Adhesion, and Cell Migration

DiMilla et al. (1993) and Palecek et al. (1997) reported

Table III. Summary of Results

| Assay                    | mAb added: | Chemoattractant* |                 |                 |      |                 |                 |      |
|--------------------------|------------|------------------|-----------------|-----------------|------|-----------------|-----------------|------|
|                          |            | fMLP             |                 |                 | LTB4 |                 |                 |      |
|                          |            | None             | Anti- $\beta_1$ | Anti- $\beta_2$ | None | Anti- $\beta_1$ | Anti- $\beta_2$ | None |
| Adhesion to fibrin*      | >40%       | >40%             | <10%            | ~50%            | ~66% | <10%            | <5%             |      |
| Chemotaxis               | –          | +                | –               | +               | +    | –               | –               |      |
| Exclusion Rh-PEG (10 kD) | 80%        | 20%              | <5%             | 20%             | 2%   | <5%             | <5%             |      |
| Binding mAb 15/7         | ~10×       | ND               | ND              | bkg             | ND   | ND              | bkg             |      |

\*Percent of control. About 40% and 60% of the added PMN adhered to the fibrin-coated surfaces in response to fMLP and LTB4, respectively. ND, not done; bkg, background.

that smooth muscle cells migrate optimally on fibronectin-coated surfaces when their integrins bind to these surfaces at intermediate strengths. Weber et al. (1996) reported an inverse correlation between the strength of adhesion of chemokine-stimulated monocytes to surfaces coated with the 120-kD RGD-containing fibronectin fragment and the capacity of these cells to migrate across filters coated with this fibronectin fragment. The findings of Keller et al. (1979) and of Wilkinson et al. (1984), and those reported in Fig. 6, demonstrate an inverse correlation between closeness of apposition of PMN to surfaces coated with proteins that express ligands for PMN receptors and the ability of PMN to migrate on or through matrices containing these proteins. Thus, it seems likely that loose versus close apposition between cells and matrix protein-coated substrates reflects weak versus strong adhesion, respectively, between the cells and the substrate.

### ***PMA Bypasses $\beta_1$ Integrins in Stimulating PMN to Adhere Closely to Fibrin***

Antibodies against  $\beta_2$  integrins reduced adhesion, inhibited close apposition between PMA-stimulated PMN and fibrin (Table II), and blocked PMN migration through fibrin (data not shown). Antibodies against  $\beta_1$  integrins had no effect on any of these parameters (Table II and data not shown). These results demonstrate that the interaction of activated  $\beta_2$  integrins with fibrin is both required and sufficient for PMA-stimulated PMN to form zones of close apposition on fibrin (Table II), and that PMA bypasses the requirement for engagement of activated  $\beta_1$  integrins by matrix proteins for PMN to form zones of close apposition on fibrin.

### ***Pathways by Which fMLP and LTB4 Activate $\beta_1$ and $\beta_2$ Integrins***

Although the signal transduction pathways by which chemoattractants regulate PMN  $\beta_1$  and  $\beta_2$  integrins remain to be elucidated, our findings lead us to make three suggestions regarding the organization of these pathways.

First, antibodies that activate  $\beta_1$  integrins do not promote adhesion of unstimulated PMN to fibrin, or inhibit LTB4-stimulated chemotaxis of PMN through fibrin gels (unpublished data). These results suggest that signals initiated by both fMLP receptors and activated  $\beta_1$  integrins are required to inhibit chemotaxis of fMLP-stimulated PMN through fibrin gels.

Second, the finding that fMLP and PMA have similar effects on PMN adhesion to and migration through fibrin

gels might suggest that the interaction of activated  $\beta_1$  integrins of fMLP-stimulated PMN with fibrin activates protein kinase C, and that this is the mechanism by which fMLP signals  $\beta_2$  integrins to bind closely to fibrin. However, Laudanna et al. (1996) reported that calphostin C, a protein kinase C inhibitor, blocks adhesion of PMA-stimulated, but not of fMLP-stimulated, mouse lymphocytes transfected with fMLP receptors, to VCAM-1-coated surfaces. (Adhesion of chemokine-stimulated lymphocytes to VCAM-1 is mediated by activated  $\alpha_4\beta_1$  integrins.) Laudanna et al. (1996) identified rho as a key participant in fMLP- and IL-8-mediated activation of  $\alpha_4\beta_1$  integrins in mouse lymphocytes. This finding suggests to us that rho acts downstream of  $G\alpha_i$  in activating  $\beta_1$  integrins. The report of Caron and Hall (1998) that rho participates in coupling CR3 (CD11b/CD18) to the actin cytoskeleton suggests that rho also affects  $\beta_2$  integrin-mediated functions. Whether PMN LTB4 receptors activate rho is unknown and should be investigated.

Third, binding of fMLP to its receptor activates  $G\alpha_i$  (Laudanna et al., 1996). The specific  $G\alpha$  activated by LTB4 in PMN has not been reported. Pertussis toxin, which inactivates  $G\alpha_i$ , blocks most effects of LTB4 and of fMLP on human PMN. Thus, the finding that fMLP activates  $\beta_1$  integrins (Fig. 5 J) while LTB4 does not (Fig. 5 F) suggests that binding of LTB4 to its receptor activates  $G\alpha$  subunits other than, or in addition to,  $G\alpha_i$  and that this difference in  $G\alpha$  subunit utilization is responsible for the divergent effects of fMLP and LTB4 on  $\beta_1$  integrin activation (Fig. 5), and on closeness of PMN adhesion to fibrin (Fig. 6). Indeed, Arai and Charo (1996) have shown differential utilization of  $G\alpha$  subunits after MCP-1 or IL-8 stimulation of MCP-1 or IL-8 receptor transfected HEK293 cells, and Yokomizo et al. (1997) have demonstrated that pertussis toxin treatment does not ablate  $Ca^{2+}$  increases stimulated by LTB4 in LTB4 receptor-bearing CHO cells.

### ***Proposed Mechanisms by Which fMLP Inhibits PMN Chemotaxis through Fibrin Gels***


Our studies suggest at least three distinct mechanisms by which fMLP could inhibit PMN migration through fibrin gels. First, the combined strengths of adhesion of activated  $\beta_1$  and  $\beta_2$  integrins to fibrin could be sufficient to immobilize PMN on fibrin. Our unpublished finding that antibodies that activate  $\beta_1$  integrins do not inhibit migration of LTB4-stimulated PMN through fibrin gels casts doubt on this combined-strength-of-adhesion hypothesis as an ex-

planation for the inhibitory effect of fMLP on PMN chemotaxis through fibrin.

Second is the possibility that binding of fMLP or LTB<sub>4</sub> to its cognate receptors directly and differentially activates  $\beta_2$  integrins for strong or weak adhesion, respectively. According to this hypothesis, fMLP-activated  $\beta_1$  integrins play no role in inhibiting chemotaxis of fMLP-stimulated PMN through fibrin. However, since activated  $\beta_1$  integrins mediate outside-in signaling, RGD peptides and antibodies against  $\beta_1$  integrins reverse fMLP's inhibitory effect on PMN migration through fibrin by stimulating  $\beta_1$  integrins to signal trans-dominant negative (Diaz-Gonzalez et al., 1996) effects on  $\beta_2$  integrins. Against this hypothesis are the findings that antibodies against the  $\alpha_6$  chains of  $\beta_1$  integrins (Fig. 3), and antibodies that activate  $\beta_1$  integrins (unpublished data), do not reverse fMLP's inhibitory effect on PMN chemotaxis through fibrin.

Third, and we think most likely, is that the capacity of fMLP to promote close adhesion to, and to block migration through, fibrin gels is mediated by a cascade of signals (diagrammed in Fig. 7), in which the interaction of activated  $\beta_1$  integrins with the fibrin matrix causes trans-dominant activation of  $\beta_2$  integrins. This mechanism is consistent with previous studies (Pommier et al., 1983; Wright et al., 1984; Brown, 1992) showing that interaction of PMN or macrophages with RGD-containing matrix proteins activates  $\alpha_M\beta_2$  integrins for phagocytosis of C3bi-coated particles.

As shown in Fig. 7, we suggest that the interaction of LTB<sub>4</sub> or fMLP with their respective PMN receptors generates a "common" signal that activates  $\beta_2$  integrins for loose adhesion to fibrin (Fig. 7, A and B, and D and E, respectively). In addition, we propose that fMLP receptors (Fig. 7 C) also signal activation of  $\alpha_5\beta_1$  integrins (Figs. 5 J and 7 E). We further suggest that binding of activated  $\alpha_5\beta_1$  integrins to fibrin matrices clusters these integrins, thereby generating an outside-in signal that activates  $\beta_2$  integrins (Fig. 7 F), for close apposition between PMN and fibrin-coated substrates (Fig. 7 G).



**Figure 7.** Proposed mechanism by which fMLP and LTB<sub>4</sub> regulate  $\beta_1$  and  $\beta_2$  integrins, and thereby regulate PMN chemotaxis through fibrin gels. See Discussion for description.

Close apposition reflects tight adhesion (Keller et al., 1979; Wilkinson et al., 1984; DiMilla et al., 1993; Palecek et al., 1997), presumably mediated by the coupling of  $\beta_2$  integrins to the cytoskeleton. We do not know whether tight adhesion causes, or is merely associated with, cessation of migration. In either case, PMN cease migrating (Figs. 2 A and 3 A, and Table III). We propose that antibodies and peptides that block the interaction of activated  $\alpha_5\beta_1$  integrins with fibrin (Figs. 2 and 3, and Table I) inhibit these outside-in signals, thereby blocking trans-dominant activation of  $\beta_2$  integrins for close apposition to fibrin (Fig. 6 and Table II) and allowing PMN to migrate through fibrin.

The interaction of LTB<sub>4</sub> with its receptor also generates a signal that stimulates  $\beta_2$  integrins for loose apposition. However, LTB<sub>4</sub> does not activate  $\beta_1$  integrins (Fig. 5 F). Therefore, these  $\beta_1$  integrins do not bind to the matrix, do not generate outside-in signals, and therefore do not initiate trans-dominant activation of  $\beta_2$  integrins for close apposition (Fig. 7, A–C), or cessation of migration.

### What Characterizes the Sessile State?

Further work is needed to determine whether cessation of migration is merely a function of strong adhesion between PMN and fibrin or whether it reflects reorganization of the PMN cytoskeleton as observed by Dustin et al. (1997) in antigen-sensitized T lymphocytes. They found that these cells become immobilized when they encounter MHC class II molecules containing a peptide antigen recognized by the T lymphocytes' antigen receptors. They identified changes in microtubule organization of these sessile T lymphocytes that distinguish them from their randomly migrating brethren. We suspect that PMN that adhere to fibrin after fMLP stimulation will exhibit similar changes in cytoskeletal organization.

### Why Are There So Many Different Chemoattractants for PMN?

Our findings suggest that the availability of many different chemoattractants (e.g., fMLP, LTB<sub>4</sub>, IL-8, C5a, etc.) serves two complementary functions. First, they provide redundancy, thereby assuring that pathogenic microbes are detected rapidly by the innate immune system. Second, they reflect the need to direct PMN to different tissue sites and to prepare them for interactions with many different types of ligands.

### Chemoattractant-encrypted Stop Signals Provide a Gradient-independent Mechanism for Leukocyte Accumulation at Specific Anatomic Sites

Our findings also suggest an alternative to the notion that leukocyte accumulation at a specific anatomic site in vivo requires the presence of a gradient of chemoattractant/chemokine emanating from that site. While there is no doubt that gradients of chemoattractants/chemokines are formed in vitro (Keller et al., 1979; Wilkinson et al., 1984; Huber et al., 1991; Campbell et al., 1996, 1997; Foxman et al., 1997; Palecek et al., 1997), they may be difficult to maintain in vivo in the face of the perturbing effects of muscular contraction and variations in blood and lymph flow.

Leukocytes in the vascular system begin to enter specific



tissue compartments when they encounter a chemoattractant/chemokine. We suggest that once within this tissue compartment leukocytes migrate randomly in response to a relatively uniform concentration of matrix-bound chemoattractant/chemokine. When in the course of this random walk they encounter extracellular matrix proteins or cells that express ligands for a specific activated  $\beta_1$  integrin, they adhere strongly and become sessile. By regulating activation of specific receptors and adhesive strengths, concentrations of chemoattractants/chemokines well below those required to saturate or desensitize chemoattractant/chemokine receptors can mediate a stochastic process by which leukocytes accumulate at specific anatomic sites and form highly ordered structures (e.g., granulomas, germinal centers). According to this model, leukocytes accumulate at specific anatomic sites by a process that is similar in principle to the accumulation of flies on fly paper.

Foxman et al. (1997) showed that multiple chemoattractants/chemokines can work in combination to elicit migration patterns that cannot be achieved by a single chemoattractant/chemokine. The mechanisms we and they have described are complementary. These mechanisms are likely to be of special importance within tissue compartments where overlapping fields of chemoattractants/chemokines/cytokines surely occur, and where cells migrate in stepwise fashion from one anatomic site to another (e.g., T cell movement in lymph nodes from T cell-rich paracortical zones to germinal centers; Garside et al., 1998), PMN accumulation at foci of bacterial infection, or of immune-complex deposition (Wilkinson et al., 1984). The essential point of the findings reported here is that by endowing leukocytes, and probably all migrating cells, with a modest number of receptors for different chemoattractants, chemokines, and cytokines, nature has made optimal use of instructive and selective mechanisms to achieve a level of organizational specificity that would otherwise require substantially more genetic information.

We thank Drs. A.R. Horwitz and Sally Zigmund for helpful discussions, Eugene Butcher and Ellen Foxman for suggestions about the manuscript, Eric Brown for sharing unpublished data, and one of the reviewers for particularly thoughtful suggestions.

This study was supported by National Institutes of Health grant AI20516, Bristol-Myers Squibb Research, and a generous gift of the late Samuel W. Rover.

Received for publication 18 May 1998 and in revised form 8 January 1999.

## References

- Anderson, D.C., and T.A. Springer. 1987. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. *Annu. Rev. Med.* 38:175-194.
- Arai, H., and I.F. Charo. 1996. Differential regulation of G-protein-mediated signaling by chemokine receptors. *J. Biol. Chem.* 271:21814-21819.
- Asakura, S., K. Niwa, T. Tomozawa, Y. Jin, S. Madoiwa, Y. Sakata, T. Sakai, H. Funayama, G. Soe, F. Forgerty, H. Hirata, and M. Matsuda. 1997. Fibroblasts spread on immobilized fibrin monomer by mobilizing a beta1-class integrin, together with a vitronectin receptor alpha v beta 3 on their surface. *J. Biol. Chem.* 272:8824-8829.
- Bohnsack, J.F., S.K. Akiyama, C.H. Damsky, W.A. Knappe, and G.A. Zimmerman. 1990. Human neutrophil adherence to laminin in vitro. Evidence for a distinct neutrophil integrin receptor for laminin. *J. Exp. Med.* 171:1221-1237.
- Bohnsack, J.F., J. Chang, X. Zhou, and T.A. Yednock. 1995. Mechanisms of beta 1 integrin-dependent adherence of granulocytic HL60 to fibronectin. *J. Leukocyte Biol.* 57:592-599.
- Brown, E.J. 1992. Complement receptors, adhesion, and phagocytosis. *Infect. Agents Dis.* 1:63-70.
- Campbell, J.J., S. Qin, K.B. Bacon, C.R. Mackay, and E.C. Butcher. 1996. Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. *J. Cell Biol.* 134:255-266.
- Campbell, J.J., E.F. Foxman, and E.C. Butcher. 1997. Chemoattractant receptor cross talk as a regulatory mechanism in leukocyte adhesion and migration. *Eur. J. Immunol.* 27:2571-2578.
- Caron, E., and A. Hall. 1998. Identification of two distinct mechanisms of phagocytosis controlled by different rho GTPases. *Science.* 282:1717-1721.
- Carter, W.G., E.A. Wayner, T.S. Bouchard, and P. Kaur. 1990. The role of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epidermal cells. *J. Cell Biol.* 110:1387-1404.
- Diamond, M., and T. Springer. 1994. The dynamic regulation of integrin adhesiveness. *Curr. Biol.* 4:506-517.
- Diaz-Gonzalez, F., J. Forsyth, B. Steiner, and M.H. Ginsberg. 1996. Trans-dominant inhibition of integrin function. *Mol. Biol. Cell.* 7:1939-1951.
- DiMilla, P.A., J.A. Stone, J.A. Quinn, S.M. Albelda, and D.A. Lauffenburger. 1993. Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. *J. Cell Biol.* 122:729-737.
- Dustin, M.L., S.K. Bromley, Z. Kan, D.A. Peterson, and E.R. Unanue. 1997. Antigen receptor engagement delivers a stop signal to migrating T lymphocytes. *Proc. Natl. Acad. Sci. USA.* 94:3909-3913.
- Farrell, D.H., and H.A. al-Mondhry. 1997. Human fibroblast adhesion to fibrinogen. *Biochemistry.* 36:1123-1128.
- Foxman, E.F., J.J. Campbell, and E.C. Butcher. 1997. Multistep navigation and the combinatorial control of leukocyte chemotaxis. *J. Cell Biol.* 139:1349-1360.
- Gao, J.X., and A.C. Issekutz. 1996. Mac-1 (CD11b/CD18) is the predominant beta 2 (CD18) integrin mediating human neutrophil migration through synovial and dermal fibroblast barriers. *Immunology.* 88:463-470.
- Gao, J.X., J. Wilkins, and A.C. Issekutz. 1995. Migration of human polymorphonuclear leukocytes through a synovial fibroblast barrier is mediated by both beta 2 (CD11/CD18) integrins and the beta 1 (CD29) integrins VLA-5 and VLA-6. *Cell. Immunol.* 163:178-186.
- Garside, P., E. Ingulli, R.R. Merica, J.G. Johnson, R.J. Noelle, and M.K. Jenkins. 1998. Visualization of specific B and T lymphocyte interactions in the lymph node. *Science.* 281:96-99.
- Gresham, H.D., I.L. Graham, G.L. Griffin, J.C. Hsieh, L.J. Dong, A.E. Chung, and R.M. Senior. 1996. Domain-specific interactions between ectactin and neutrophil integrins. G2 domain ligation of integrin alpha3 beta1 and E domain ligation of the leukocyte response integrin signal for different responses. *J. Biol. Chem.* 271:30587-30594.
- Huber, A.R., S.L. Kunkel, R.F.D. Todd, and S.J. Weiss. 1991. Regulation of transendothelial neutrophil migration by endogenous interleukin-8 [published errata appear in *Science*. 1991. 254:631 and 254:1435]. *Science.* 254:99-102.
- Keller, H.U., S. Barandun, P. Kistler, and J.S. Ploem. 1979. Locomotion and adhesion of neutrophil granulocytes. Effects of albumin, fibrinogen and gamma globulins studied by reflection contrast microscopy. *Exp. Cell Res.* 122:351-362.
- Lallier, T., and M. Bronner-Fraser. 1991. Avian neural crest cell attachment to laminin: involvement of divalent cation dependent and independent integrins. *Development.* 113:1069-1084.
- Laudanna, C., J.J. Campbell, and E.C. Butcher. 1996. Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. *Science.* 271:981-983.
- Lawson, M.A., and F.R. Maxfield. 1995. Ca(2+) and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils. *Nature.* 377:75-79.
- Loike, J.D., B. Sodeik, L. Cao, S. Leucona, J.I. Weitz, P.A. Detmers, S.D. Wright, and S.C. Silverstein. 1991. CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. *Proc. Natl. Acad. Sci. USA.* 88:1044-1048.
- Loike, J.D., R. Silverstein, S.D. Wright, J.I. Weitz, A.J. Huang, and S.C. Silverstein. 1992. The role of protected extracellular compartments in interactions between leukocytes, and platelets, and fibrin/fibrinogen matrices. *Ann. NY Acad. Sci.* 667:163-172.
- Loike, J.D., R. Silverstein, L. Cao, L. Solomon, J. Weitz, E. Haber, G.R. Matsueda, M.S. Bernatowicz, and S.C. Silverstein. 1993. Activated platelets form protected zones of adhesion on fibrinogen and fibronectin-coated surfaces. *J. Cell Biol.* 121:945-955.
- Loike, J.D., J. El Khoury, L. Cao, C.P. Richards, H. Rascoff, J.T. Mandeville, F.R. Maxfield, and S.C. Silverstein. 1995. Fibrin regulates neutrophil migration in response to interleukin 8, leukotriene B4, tumor necrosis factor, and formyl-methionyl-leucyl-phenylalanine. *J. Exp. Med.* 181:1763-1772.
- McCormick, B.A., P.M. Hofman, J. Kim, D.K. Carnes, S.I. Miller, and J.L. Madara. 1995. Surface attachment of *Salmonella typhimurium* to intestinal epithelia imprints the subepithelial matrix with gradients chemotactic for neutrophils. *J. Cell Biol.* 131:1599-1608.
- Miettinen, H.M., J.M. Gripenrot, and A.J. Jesaitis. 1998. Chemotaxis of Chinese hamster ovary cells expressing the human neutrophil formyl peptide receptor: role of signal transduction molecules and alpha5 beta1 integrin. *J. Cell Sci.* 111:1921-1928.
- Palecek, S.P., J.C. Loftus, M.H. Ginsberg, D.A. Lauffenburger, and A.F. Horwitz. 1997. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness [published erratum appears in *Nature*. 1997. 388:210]. *Nature.* 385:537-540.

- Patel, Y., S. Rahman, A. Siddiqua, J.M. Wilkinson, V.V. Kakkar, and K.S. Authi. 1998. Functional characterization of PM6/13, a beta3-specific (GPIIIa/CD61) mAb that shows preferential inhibition of fibrinogen binding over fibronectin binding to activated human platelets. *Thromb. Haemost.* 79:177-185.
- Pierschbacher, M.D., and E. Ruoslahti. 1987. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. *J. Biol. Chem.* 262:17294-17298.
- Pommier, C.G., S. Inada, L.F. Fries, T. Takahashi, M.M. Frank, and E.J. Brown. 1983. Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. *J. Exp. Med.* 157:1844-1854.
- Premack, B.A., and T.J. Schall. 1996. Chemokine receptors: gateways to inflammation and infection. *Nat. Med.* 2:1174-1178.
- Smith, C.W. 1993. Leukocyte-endothelial cell interactions. *Semin. Hematol.* 30:45-55.
- Springer, T.A. 1995. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. *Annu. Rev. Physiol.* 57:827-872.
- Suehiro, K., J. Gailit, and E.F. Plow. 1997. Fibrinogen is a ligand for integrin alpha5 beta1 on endothelial cells. *J. Biol. Chem.* 272:5360-5366.
- Tang, T., A. Rosenkranz, K.J.M. Assmann, M.J. Goodman, J.C. Gutierrez-Ramos, M.C. Carroll, R.S. Cotran, and T.N. Mayadas. 1997. A role for Mac-1 (CD11b/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fc gamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. *J. Exp. Med.* 186:1853-1863.
- Weber, C., R. Alon, B. Moser, and T.A. Springer. 1996. Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis. *J. Cell Biol.* 134:1063-1073.
- Werr, J., X. Xie, P. Hedqvist, E. Ruoslahti, and L. Lindbom. 1998. Beta1 integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo. *J. Exp. Med.* 187:2091-2096.
- Wilkinson, P.C., J.M. Lackie, J.V. Forrester, and G.A. Dunn. 1984. Chemokinetic accumulation of human neutrophils on immune complex-coated substrata: analysis at a boundary. *J. Cell Biol.* 99:1761-1768.
- Wright, S.D., and S.C. Silverstein. 1982. Tumor-promoting phorbol esters stimulate C3b and C3bi receptor-mediated phagocytosis in cultured human monocytes. *J. Exp. Med.* 156:1149-1164.
- Wright, S.D., P.E. Rao, W.C. Van Voorhis, L.S. Craigmyle, K. Iida, M.A. Talle, E.F. Westberg, G. Goldstein, and S.C. Silverstein. 1983. Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. *Proc. Natl. Acad. Sci. USA.* 80:5699-5703.
- Wright, S.D., M.R. Licht, L.S. Craigmyle, and S.C. Silverstein. 1984. Communication between receptors for different ligands on a single cell: ligation of fibronectin receptors induces a reversible alteration in the function of complement receptors on cultured human monocytes. *J. Cell Biol.* 99:336-339.
- Wright, S.D., J.I. Weitz, A.J. Huang, S.M. Levin, S.C. Silverstein, and J.D. Loike. 1988. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. *Proc. Natl. Acad. Sci. USA.* 85:7734-7738.
- Yokomizo, T., T. Izumi, K. Chang, Y. Takuwa, and T. Shimizu. 1997. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. *Nature.* 387:620-624.